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Abstract
Background: Osteoarthritis-induced arthralgia is a common cause of morbidity in both men and
women worldwide. AR7 Joint Complex is a nutritional supplement containing various ingredients
including sternum collagen II and methylsulfonylmethane. The product has been marketed in United
States for over a decade, but clinical data measuring the effectiveness of this supplement in relieving
arthralgia is lacking. The goal of this study was to determine the effect of AR7 Joint Complex on
osteoarthritis.
Methods: A total of 100 patients over the age of 50 who had osteoarthritis were recruited to the
double-blind study and randomly assigned into either treatment or placebo control groups. The
patients in the treatment group were given AR7 Joint Complex orally, 1 capsule daily for 12 weeks,
while the patients in the control group were given a placebo for the same period of time. Prior to
and at the end of the study, data including Quality of Life questionnaires (SF-36), visual analog scales
(1 to 100 mm), and X-rays of affected joints were collected.
Results: A total of 89 patients completed the study: 44 from the treatment group and 45 from the
control group. No significant change in X-ray results was found in either group after the study.
However, there was a significant decrease in patients complaining of arthralgia and tenderness (P
< 0.01) in the treatment group and there was also a significant difference between the treatment
and control groups at the end of the study. In addition, for Quality of Life data, the body pain index
(BP) in the treatment group was significantly improved (P < 0.05) compared to the control group.
No significant toxicity was noted in either group.
Conclusion: AR7 Joint Complex appears to have short-term effects in relieving pain in patients
with osteoarthritis. Whether such an effect is long-lasting remains to be seen.
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Osteoarthritis (OA), or degenerative joint disease, is the
most common form of arthritis and affects almost all
joints, especially weight-bearing joints [1]. It affects both
men and women of all races [2]. Its prevalence increases
with age and is almost universal in individuals over the
age of 75. In essence, it is a degenerative disease related to
aging. Clinically, OA is characterized by progressive dete-
rioration and loss of articular cartilage accompanied by
proliferation of new bone and soft tissue in and around
the involved joint [3]. Symptoms include joint pain,
swelling, stiffness, and crepitus. The pain usually begins
insidiously, in the form of a deep, aching, poorly localized
pain occurring with the use of the involved joint and
relieved by rest. Stiffness occurs in the morning and after
periods of inactivity. Crepitus may occur with joint move-
ment due to loss of cartilage. The most common clinical
findings in physical examinations include the formation
of Heberden's nodes (enlarged dorsomedial and lateral
aspects of the distal interphalangeal joint) in the early
stage and osteophytes, as well as severe deformity accom-
panied by joint sclerosis at a later stage [4].
The pathogenesis of OA is poorly understood, but inflam-
mation appears to play an important role [5]. Breakdown
products of cartilage stimulate the release of collagenase
and other hydrolytic enzymes from cells in the synovium.
The presence of immunoglobulin and complement in the
superficial layer of cartilage suggest that immune com-
plexes may induce an inflammatory response. Recently,
cyclooxygenase-2 (COX-2) selective nonsteroidal anti-
inflammatory drugs (NSAIDs), for example Celebrex,
have been shown to be as effective as acetaminophen and
nonselective NSAIDs in treating OA (for a recent review,
see ref [6]). This finding highlights the importance of the
inflammatory mechanism in the pathogenesis of this dis-
ease. There is no specific laboratory test to help establish
the clinical diagnosis of OA. Radiographs of the involved
joints are initially normal, but as the disease progresses,
joint space narrowing, eburnation, and osteophytes are
observed. The treatment includes the use of NSAIDs,
intra-articular steroid injection, and orthopedic surgery
[5].
AR7 Joint Complex is a nutritional supplement that has
been available on the market for over a decade with no
serious side effects reported. It contains sternum collagen,
methylsulfonylmethane (MSM), cetyl myristoleate
(CMO), lipase, turmeric, vitamin C, and bromelain. How-
ever, the benefits of this supplement in relieving symp-
toms of OA have not been tested in a clinical setting. The
rationale of this project was to examine the short-term
effects of AR7 in relieving symptoms, mainly joint pain
and stiffness, in patients who suffer from OA. The findings
might provide preliminary data to determine the benefits
of AR7 as an alternative, non-surgical method for patients
with OA.
Methods
Materials
AR7 in the form of softgels were provided by Robinson
Pharma (Orange County, CA, USA). The product was
manufactured following cGMP guidelines. The main
ingredients of AR7 included sternum collagen, methylsul-
fonylmethane (MSM), cetyl myristoleate (CMO), lipase,
vitamin C, and bromelain. The main ingredient of the pla-
cebo softgel was corn oil. In addition, there were gelatin,
glycerin, purified water and titanium dioxide, and artifi-
cial food coloring. The placebo control pill was also man-
ufactured by Robinson Pharma.
Subjects
All subjects were identified and recruited from 2 commu-
nity health centers in Shanghai, People's Republic of
China: the Zha Pu community health service center and
Tang Qiao community health service center. All patients
were screened by American College of Rheumatology cri-
teria [7]. The inclusion criteria included patients who
were: over 50 years old at screening, either male or female,
and displayed symptoms of degenerative joint diseases,
including joint pain, stiffness, swelling, and difficulty
walking and/or getting up/down stairs. All patients were
free from the following diseases: cancer, gallstone, ulcers,
and gout. None of them were taking bromelain, antibiot-
ics (including amoxicillin and tetracycline), antiplatelet
drugs, or warfarin. The study was reviewed and approved
by the Internal Review Boards of the Zha Pu and Tang
Qiao community health service centers, and consent was
obtained from each of the study subjects.
According to the above stated inclusion/exclusion criteria,
a total of 100 patients were recruited and randomly
assigned into 2 groups: a treatment group and a control
group, with 50 patients in each group. Among them, 11
patients withdrew from the study – 2 patients moved
away, 2 decided to undergo physical therapy instead, 3
showed mild stomach discomfort after taking the pill
within the first 2 weeks of the study, and the remaining 4
had difficulty making multiple hospital visits. As a result,
44 patients in the treatment group and 45 patients in the
control group completed the study.
Patient entry and randomization
Patients were enrolled in the study once the informed-
consent form was signed. Each subject was blindly rand-
omized into either the treatment (Group 1) or control
group (Group 2). Simple randomization was conducted
using random numbers from a computer-generated
sequence. The randomization was conducted centrally in
Dr. Shi's department at Shanghai Jiatong University. AtPage 2 of 6
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study selected an envelope assigning him/her to one of
the 2 groups. After randomization, each subject received a
container marked with a colored label (e.g., red or blue)
with 30 softgel capsules inside. Treatment blinding was
maintained throughout the study period. Each subject
took 1 color-coded capsule orally and daily with water,
immediately after breakfast.
Physicians at each facility were responsible for performing
clinical examinations, ordering and interoperating labora-
tory testing, and x-ray findings. They were also responsible
for filling out the SF-36 form. They were trained by inves-
tigators at Shanghai Jiaotong University (Dr. Shi and Dr.
Xie) prior to initiation of the study.
Baseline assessment and laboratory testing
Each subject's date of birth, sex, race, medical history, cur-
rent medications, and alcohol history were obtained by
the investigators using a standard SF-36 questionnaire at
the time of the initial screening prior to randomization.
Physical examinations were performed by local physi-
cians, focusing on joint conditions, and a standardized
form was used to record findings. Laboratory tests were
performed at the beginning and end of the study. Tests
included: blood tests for CBC and Serum BUN/Creati-
nine; urine tests with clean-catch urine samples for dip-
stick analysis of hematuria and pH; and uric acid analysis
(to rule out gout). X-rays of affected joints were also taken
to document the degree of joint space narrowing, eburna-
tion, and osteophytes.
Study duration and patient follow-up
All study subjects were recruited within the first 2 weeks of
the study. Each subject was then monitored for 3 months.
The treatment period for each subject was exactly 3
months. Specific tests, as outlined above, were performed
after the 2-week washout phase and again at the end of the
study (3 months later). All subjects were asked to return to
the clinic on a weekly basis for the first month and on a
monthly basis for the remaining 3 months. At each visit,
the investigators addressed concerns that the subject had,
evaluated compliance and toxicity, and resupplied addi-
tional capsules. The capsules remaining in the returned
bottle were counted and recorded. Records of other drugs
taken at the same period were also taken.
Quality of life measurement
The study used the standard "Health Survey" (SF-36) to
measure quality of life of the studied subjects. The major
components included physical function (or limitations of
activity, PF), social function (or social activities, SF), phys-
ical health problems (PHP), emotional health problems
(EHP), body pain (BP), vitality (VT), mental health (or
energy and emotions, MH), and general health (GH). SF-
36 surveys were conducted at the baseline and each fol-
low-up visit by a physician was conducted in a blind fash-
ion (without knowing if the subject was in the treatment
or placebo group). All questionnaire data were coded
according to severity from lowest to highest, and then
summarized with one numerical score for each category
where higher scores corresponded to better health status.
Data analysis
The database was managed by the EpiData 3.0 system
using SPSS 11.0 software for data analysis. For quantita-
tive measurements, a Student's t-test was used to compare
the results of the treatment and control groups while a
paired t-test was used for comparing before-and-after data
for each group. For qualitative data, chi-square analysis
and the Wilcoxon Rank Sum test were used.
Results
Baseline data
The 89 subjects had an average age of 62.54 ± 9.05. They
consisted of 21 males and 68 females. The control and
treatment groups showed similar age compositions
(mean age 63.27 ± 9.03 versus 61.82 ± 9.11, respectively)
and gender distribution (Χ2 = 2.85, P = 0.09).
The reported OA symptoms for each subject ranged from
1–39 years with an average of 9.10 ± 8.14 years. At the
baseline, the 2 groups showed no significant differences
in the length of time since onset of OA, history of taking
steroid medication, and joint symptoms including joint
pain, stiffness, tenderness, and limitation of activity (P >
0.05 for all, Table 1). Thus, the 2 groups were well-bal-
anced. X-ray examinations also showed a similar degree of
changes in joint narrowing, eburnation, and osteophytes
in both groups (data not shown).
Results after intervention
After a 3-month study period, the percentage of patients
reported to have joint pain, stiffness, and tenderness were
significantly decreased in the treatment group versus the
control group (Table 2). No serious or unexpected adverse
events associated with the capsules were found. No signif-
icant difference was seen for limitation of activity between
the 2 groups (Table 2) and X-ray data also did not show
any significant changes between them (data not shown).
Compared to the baseline (Table 1), however, the percent-
age of patients complaining of joint pain, stiffness, tender-
ness, and even limitation of activity were significantly
decreased after the study in the treatment group, but not
in the control group.
When quality of life questionnaire data were analyzed
item by item, we observed that there were no significant
differences between the 2 groups at the baseline in any of
the categories. After the study, there was a significantlyPage 3 of 6
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versus the control group (64.07 ± 14.22 versus 55.76 ±
18.00, respectively, P = 0.02, Table 3). Other categories
including physical function (PF, or limitations of activ-
ity), physical health problems (PHP), vitality (VT), social
function (SF, or social activities), emotional health prob-
lems (EHP), mental health (MH, or energy and emo-
tions), and general health (GH) did not show a
statistically significant difference between the two groups.
In the treatment group, statistically significant improve-
ments of scores were observed at the end of the study
compared to the beginning for all categories except social
function (SF) (P < 0.01 for all except SF by paired t-test,
Table 3). However, such a change was also observed,
although to a lesser a degree, in some categories (BHP,
EHP, and GH) in the control group as well, suggesting
some placebo effects might be present.
Discussion
OA is a common disease affecting middle-aged to elderly
people [3]. Though the mortality rate of OA may be low,
the morbidity and effect on quality of life can be quite
substantial. Research has shown that people with OA not
only have reduced body function and social function, but
also low moods, pain, fatigue, and reduced quality of life
[8]. People with joint disease have a tendency to be
depressed when compared to healthy individuals [9]. Cur-
rently, the main treatments for OA are nonsteroidal anti-
inflammatory drugs (NSAIDs). But these treatments can-
not inhibit OA degeneration. In addition, long-term use
of these drugs has shown many side effects.
AR7 Joint Complex is a dietary supplement containing
sternum collagen type II, methylsulfonylmethane (MSM),
cetyl myristoleate (CMO), vitamin C, bromelain, tur-
meric, and lipase. Collagen type II is the major ingredient
in this nutritional supplement. As a major component of
joint cartilage, it is important in maintaining joint func-
tion. A study has shown that collagen type II may suppress
the local immune response, which may delay cartilage
degeneration and inhibit chronic inflammation [10].
Interestingly, Whitacre reported that OA patients misdiag-
nosed with rheumatoid arthritis showed significantly
improved joint symptoms after taking collagen type II
[11]. Yet another study reported that collagen type II
Table 1: Comparison of baseline percentages of positive findings in treatment and control groups
Positive (%)
Items Treatment
(n = 44)
Control
(n = 45)
Χ2 Value P Value
Age 63.27 61.82
Sex M/F (15.9/84.1) M/F (31.1/68.9) 2.852 0.091
X-ray findings* 100% 100%
Taking medication 45.5 31.1 1.93 0.164
Joint pain 95.5 82.2 2.69 0.101
Joint stiffness 47.7 53.3 0.28 0.597
Joint tenderness 84.1 77.8 0.57 0.449
Joint activity limitation 61.4 46.7 1.93 0.164
*All patients recruited to the study showed similar degrees of x-ray findings including joint space narrowing, eburnation, and osteophytes.
Table 2: Comparison of percentages of positive findings in 
treatment versus control groups after 12-week clinical study
Positive(%)
Items Treatment
(n = 44)
Control
(n = 45)
Χ2 Value P Value
Joint pain 43.2* 71.1
Joint stiffness 22.7* 42.2 3.85 0.050
Joint tenderness 45.5* 71.1 6.03 0.014
Joint activity limitation 27.3* 44.4 2.85 0.091
* P < 0.01 when comparing these variables before versus after the 
study in the treatment group.Page 4 of 6
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that it may reduce the joint degeneration seen in OA
patients [12].
Other ingredients contained in AR7 Joint Complex such
as MSM, CMO, bromelain, turmeric, lipase, and vitamin
C are widely considered to have some potential beneficial
effects on joint disease, but the evidence is less clear. For
example, MSM provides a rich source of sulfur, which is a
required structural mineral found in connective tissue
including mucopolysaccharides and fibrous cartilage that
maintain elasticity and flexibility [13]. CMO, on the other
hand, is a fatty acid ester that serves as a surfactant to
lubricate the involved joints [14]. Bromelain is derived
from pineapple and it is believed to be a smooth muscle
relaxant, helping to relieve cramping, alleviate joint dis-
comfort and swelling, and increase joint mobility [14].
Turmeric (Curcuma longa) is a perennial herb of the ginger
family, which has been used in Ayurvedic medicine to
decrease redness and swelling [15]. However, few scientif-
ically sound reports are available to substantiate the
claims of these components.
The results of the current study show that after taking AR7
Joint Complex the treatment group had a significantly
decreased percentage of patients complaining of joint
pain and tenderness compared to the control group
(Table 2). Significant improvement was also observed
when comparing pre- and post-study data in the treat-
ment group for joint pain, stiffness, tenderness, and limi-
tation of activity. No significant improvement was noted
in the control group. A similar trend was also observed
when quality of life data were analyzed item by item
(Table 3). Together, these findings suggest that there is evi-
dence that AR7 Joint Complex may provide anti-arthralgia
effects in OA patients. However, these effects were
observed when comparing the data from the baseline to
the end of the three-month study. At this time, we do not
know how long it takes to achieve the effects, nor do we
know how long they will last either with or without con-
tinued application of AR7 Joint Complex. But it is clear
from this short-term study that no significant changes of
X-ray findings are seen with the short-term treatment. This
may be due to the fact that many of the patients studied
have long-standing history of OA (average 9 years) and
such a short-term treatment would be unlikely to have a
substantial effect on reversing the structural damage.
Alternatively, AR7 Joint Complex may only provide anti-
inflammatory effects that have little to do with degenera-
tive joint changes.
There were some significant improvements in several var-
iables for quality of life data in the control group (PHP,
EHP, and GH) before and after the study, although the
magnitude of improvement was substantially smaller
compared to the treatment group for each variable (Table
3). This finding suggests the presence of a placebo effect.
However, since there was no significant change in the per-
Table 3: Quality of Life for treatment group compared to control group before and after clinical study
Before (  ± S) After (  ± S)
Items Treatment
(n = 44)
Control
(n = 45)
P Value Treatment
(n = 44)
Control
(n = 45)
P Value
PF 50.57 ± 25.00 52.44 ± 25.97 0.729 61.82 ± 26.31* 55.78 ± 25.69 0.276
PHP 40.10 ± 6.05 43.76 ± 6.52 0.690 54.55 ± 40.22* 58.89 ± 42# 0.636
BP 50.82 ± 14.36 51.64 ± 15.92 0.798 64.07 ± 14.22* 55.76 ± 18.00 0.020
VT 54.55 ± 15.58 58.78 ± 14.89 0.194 58.41 ± 14.21* 61.89 ± 15.79 0.278
SF 73.99 ± 16.24 69.63 ± 17.63 0.229 74.24 ± 13.51 77.28 ± 18.49 0.379
EHP 16.29 ± 19.85 24.81 ± 23.20 0.066 53.03 ± 47.31* 52.60 ± 45.22* 0.965
MH 60.82 ± 13.46 66.40 ± 16.52 0.085 65.64 ± 13.18* 67.91 ± 16.35 0.472
GH 49.54 ± 14.45 52.43 ± 15.94 0.373 61.68 ± 19.68* 61.44 ± 19.85* 0.955
*: P < 0.01;
#: P < 0.05.
PF: physical function (or limitations of activity); PHP, physical health problems; BP, body pain; VT, vitality; SF, social function (or social activities); 
EHP, emotional health problems, MH, mental health (or energy and emotions); and GH, general health.
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centage of patients reporting joint symptoms before and
after the study in the control group overall, such a placebo
effect should be rather limited.
The exact pain-relieving mechanisms of AR7 Joint Com-
plex in the OA patients remain to be determined. AR7
Joint Complex may function in the following ways: 1) it
may help correct or balance enzyme activities, thereby
inhibiting the activities of cartilage matrix degeneration;
2) it may enhance joint flexibility by lubricating joints
and relaxing surrounding muscles; 3) it may have an anti-
inflammatory effect in the joint.
While some short-term benefits of AR7 in relieving symp-
toms of OA have been observed in this placebo-controlled
randomized study, it should be noted that the sample size
was relatively small and the duration was short. Therefore,
caution should be taken into consideration when inter-
preting the data, and additional studies with larger sample
sizes and longer-term treatment may be necessary to test
the effectiveness of AR7 on OA patients.
Conclusion
In summary, this short-term placebo-controlled study
showed that the nutritional supplement AR7 Joint Com-
plex can help alleviate pain associated with OA. However,
the study is limited by a small sample size and short-term
treatment. Long-term effects and the actual mechanisms
remain to be studied.
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